Mianserin: is the intraperitoneal route of administration the best?
A 1 h pretreatment with s.c. mianserin (0.5 mg kg-1) markedly blunted the oedema of the rat paw induced by the subplantar injection of 5-HT (5 micrograms). In contrast, i.p. mianserin (same dose) failed to modify 5-HT-induced oedema. However, pretreatment with SKF-525-A (40 mg kg-1) resulted in a profound potentiation of the action of i.p. mianserin, the effect of the combination of SKF-525-A and i.p. mianserin rivaling that of s.c. mianserin. It is concluded that i.p. mianserin is metabolized by the rat liver to compounds which possess a reduced propensity to block peripheral 5-HT receptors and that the i.p. route of administration is not to be recommended when mianserin is being studied as a 5-HT receptor antagonist in the rat.
D000818:Animals; D003984:Dibenzazepines / Q000008:administration & dosage*; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy*; D007274:Injections, Intraperitoneal; D008297:Male; D008803:Mianserin / Q000008:administration & dosage* / Q000627:therapeutic use; D011335:Proadifen / Q000008:administration & dosage; D051381:Rats; D011919:Rats, Inbred Strains; D012701:Serotonin / Q000633:toxicity
D003984:Dibenzazepines; D008803:Mianserin; D012701:Serotonin; D011335:Proadifen